Cargando…

Gabapentin-Associated Movement Disorders: A Literature Review

Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized adverse drug reactions. They are commonly not discussed with patients, and their sudden occurrence can lead to misdiagnosis. This literature review aims to evaluate the clinical–epidemiological profile, pathological m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rissardo, Jamir Pitton, Medeiros Araujo de Matos, Ursula, Fornari Caprara, Ana Letícia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536490/
https://www.ncbi.nlm.nih.gov/pubmed/37755242
http://dx.doi.org/10.3390/medicines10090052
_version_ 1785112877848330240
author Rissardo, Jamir Pitton
Medeiros Araujo de Matos, Ursula
Fornari Caprara, Ana Letícia
author_facet Rissardo, Jamir Pitton
Medeiros Araujo de Matos, Ursula
Fornari Caprara, Ana Letícia
author_sort Rissardo, Jamir Pitton
collection PubMed
description Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized adverse drug reactions. They are commonly not discussed with patients, and their sudden occurrence can lead to misdiagnosis. This literature review aims to evaluate the clinical–epidemiological profile, pathological mechanisms, and management of GBP-associated MD. Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1990 and 2023. Results: A total of 99 reports of 204 individuals who developed a MD associated with GBP were identified. The MDs encountered were 135 myoclonus, 22 dyskinesias, 7 dystonia, 3 akathisia, 3 stutterings, 1 myokymia, and 1 parkinsonism. The mean and median ages were 54.54 (SD: 17.79) and 57 years (age range: 10–89), respectively. Subjects were predominantly male (53.57%). The mean and median doses of GBP when the MD occurred were 1324.66 (SD: 1117.66) and 1033 mg/daily (GBP dose range: 100–9600), respectively. The mean time from GBP-onset to GBP-associated MD was 4.58 weeks (SD: 8.08). The mean recovery time after MD treatment was 4.17 days (SD: 4.87). The MD management involved GBP discontinuation. A total of 82.5% of the individuals had a full recovery in the follow-up period. Conclusions: Myoclonus (GRADE A) and dyskinesia (GRADE C) were the most common movement disorders associated with GBP.
format Online
Article
Text
id pubmed-10536490
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105364902023-09-29 Gabapentin-Associated Movement Disorders: A Literature Review Rissardo, Jamir Pitton Medeiros Araujo de Matos, Ursula Fornari Caprara, Ana Letícia Medicines (Basel) Review Background: Gabapentin (GBP)-induced movement disorders (MDs) are under-recognized adverse drug reactions. They are commonly not discussed with patients, and their sudden occurrence can lead to misdiagnosis. This literature review aims to evaluate the clinical–epidemiological profile, pathological mechanisms, and management of GBP-associated MD. Methods: Two reviewers identified and assessed relevant reports in six databases without language restriction between 1990 and 2023. Results: A total of 99 reports of 204 individuals who developed a MD associated with GBP were identified. The MDs encountered were 135 myoclonus, 22 dyskinesias, 7 dystonia, 3 akathisia, 3 stutterings, 1 myokymia, and 1 parkinsonism. The mean and median ages were 54.54 (SD: 17.79) and 57 years (age range: 10–89), respectively. Subjects were predominantly male (53.57%). The mean and median doses of GBP when the MD occurred were 1324.66 (SD: 1117.66) and 1033 mg/daily (GBP dose range: 100–9600), respectively. The mean time from GBP-onset to GBP-associated MD was 4.58 weeks (SD: 8.08). The mean recovery time after MD treatment was 4.17 days (SD: 4.87). The MD management involved GBP discontinuation. A total of 82.5% of the individuals had a full recovery in the follow-up period. Conclusions: Myoclonus (GRADE A) and dyskinesia (GRADE C) were the most common movement disorders associated with GBP. MDPI 2023-09-06 /pmc/articles/PMC10536490/ /pubmed/37755242 http://dx.doi.org/10.3390/medicines10090052 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rissardo, Jamir Pitton
Medeiros Araujo de Matos, Ursula
Fornari Caprara, Ana Letícia
Gabapentin-Associated Movement Disorders: A Literature Review
title Gabapentin-Associated Movement Disorders: A Literature Review
title_full Gabapentin-Associated Movement Disorders: A Literature Review
title_fullStr Gabapentin-Associated Movement Disorders: A Literature Review
title_full_unstemmed Gabapentin-Associated Movement Disorders: A Literature Review
title_short Gabapentin-Associated Movement Disorders: A Literature Review
title_sort gabapentin-associated movement disorders: a literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536490/
https://www.ncbi.nlm.nih.gov/pubmed/37755242
http://dx.doi.org/10.3390/medicines10090052
work_keys_str_mv AT rissardojamirpitton gabapentinassociatedmovementdisordersaliteraturereview
AT medeirosaraujodematosursula gabapentinassociatedmovementdisordersaliteraturereview
AT fornaricapraraanaleticia gabapentinassociatedmovementdisordersaliteraturereview